---
title: "Valiant's shareholder LUYIN INVEST has cumulatively increased its holdings by 7.7787 million shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234392313.md"
description: "According to the Zhitong Finance APP, Valiant announced that its shareholder LUYIN INVEST increased its holdings of the company's shares by a total of 7.7787 million shares through self-owned funds and a special loan for stock increases via centralized bidding from March 18, 2025, to April 3, 2025"
datetime: "2025-04-03T10:39:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234392313.md)
  - [en](https://longbridge.com/en/news/234392313.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234392313.md)
generator: "portal-rs"
---

# Valiant's shareholder LUYIN INVEST has cumulatively increased its holdings by 7.7787 million shares

According to the Zhitong Finance APP, Valiant (002643.SZ) announced that its shareholder LUYIN INVEST will increase its holdings of the company's shares by a total of 7.7787 million shares through self-owned funds and special loans for stock increases via centralized bidding from March 18, 2025, to April 3, 2025

### Related Stocks

- [002643.CN](https://longbridge.com/en/quote/002643.CN.md)
- [600784.CN](https://longbridge.com/en/quote/600784.CN.md)

## Related News & Research

- [Viewtrix Technology Starts Preparations for Mainland A Share Listing](https://longbridge.com/en/news/297765151.md)
- [Air China GAAP EPS of -RMB 0.13, revenue of RMB 89.27B](https://longbridge.com/en/news/297480690.md)
- [BYD launches Sealion 08 SUV, bolstering Ocean lineup's flagship push](https://longbridge.com/en/news/297765654.md)
- [SOTL: Record revenue, margin expansion, and innovation drive robust growth and future optimism](https://longbridge.com/en/news/297615048.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**